Q-omics provides the consensus-scored RIPPLY2 profile across patient tissues and cancer cell-line models. RIPPLY2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RIPPLY2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RIPPLY2 RNA expression shows 11,132 significant gene co-expression associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, COAD, and GBM as cancer lineages where RIPPLY2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIPPLY2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIPPLY2 survival associations across molecular data types. RIPPLY2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIPPLY2 RNA expression–survival associations across cancer types. High RIPPLY2 expression shows unfavorable associations in UCEC, SARC and DLBC, but favorable associations in LGG, PAAD and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RIPPLY2 RNA expression.
This table summarizes RIPPLY2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RIPPLY2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIPPLY2 shows lower tumor expression in COAD, THCA, KIRC and UCEC and higher tumor expression in HNSC and LUSC. The COAD box plot shows higher RIPPLY2 RNA expression in normal versus tumor tissue (log2 FC = −0.514, t-test p < 0.001).
This table shows molecular features associated with RIPPLY2 in patient tissues and cancer cell lines. In patient samples, RIPPLY2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIPPLY2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
